Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Lymphoid 4Gastrointestinal 4Thoracic 3Sarcoma 3Other solid neoplasm 3Head & Neck 3Genitourinary 3Tumor-Agnostic 2Plasma cell 2Myeloid 2Dermatologic 2Breast 2Other hematologic neoplasm 1Gynecologic 1Endocrine 1

Conditions

Wilms Tumor 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Sarcoma, Ewing 1Histiocytic Sarcoma 1

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 57Azacitidine 52fludarabine phosphate 50Specimen Handling 44Whole-Body Irradiation 40ruxolitinib 37Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Stem Cell Transplantation 27Decitabine 27Granulocyte Colony-Stimulating Factor 21asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Injections 18Thiotepa 17Filgrastim 17nilotinib 15X-Rays 14Methotrexate 14Cyclosporine 14Imatinib Mesylate 13Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
larotrectinib × Myeloid × 1 year × Clear all
NCT03213704 2026-06-02

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
9 enrolled 12 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡